rs140806722
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_022132.5(MCCC2):c.599T>A(p.Ile200Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00385 in 1,614,066 control chromosomes in the GnomAD database, including 18 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_022132.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MCCC2 | NM_022132.5 | c.599T>A | p.Ile200Asn | missense_variant | 6/17 | ENST00000340941.11 | NP_071415.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MCCC2 | ENST00000340941.11 | c.599T>A | p.Ile200Asn | missense_variant | 6/17 | 1 | NM_022132.5 | ENSP00000343657.6 |
Frequencies
GnomAD3 genomes AF: 0.00250 AC: 380AN: 152198Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00210 AC: 528AN: 251438Hom.: 2 AF XY: 0.00209 AC XY: 284AN XY: 135898
GnomAD4 exome AF: 0.00399 AC: 5838AN: 1461750Hom.: 18 Cov.: 31 AF XY: 0.00374 AC XY: 2717AN XY: 727200
GnomAD4 genome AF: 0.00250 AC: 381AN: 152316Hom.: 0 Cov.: 32 AF XY: 0.00232 AC XY: 173AN XY: 74478
ClinVar
Submissions by phenotype
3-methylcrotonyl-CoA carboxylase 2 deficiency Uncertain:4Benign:1Other:1
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 14, 2023 | The MCCC2 c.599T>A; p.Ile200Asn variant (rs140806722) has been reported in two asymptomatic individuals who also harbored a frameshift variant in the other MCCC2 allele; clinical information was not provided for one of these individuals, but the other had elevated 3-hydroxyisovaleric acid and 3-hydroxyisovalerylcarnitine (Grünert 2012 and Shepard 2015). The variant is reported as a variant of uncertain significance by multiple laboratories in ClinVar (Variant ID: 167278), and is found in the non-Finnish European population with an overall allele frequency of 0.39% (495/126,690 alleles, including 2 homozygotes) in the Genome Aggregation Database. The isoleucine at codon 200 is moderately conserved, and computational analyses (SIFT: tolerated, PolyPhen2: benign) predict conflicting effects of this variant on protein structure/function. Due to limited information, the clinical significance of the p.Ile200Asn variant is uncertain at this time. - |
not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. - |
Uncertain significance, criteria provided, single submitter | curation | SIB Swiss Institute of Bioinformatics | May 31, 2018 | This variant is interpreted as a Uncertain Significance - Insufficient Evidence, for MCC2D, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PM3 => For recessive disorders, detected in trans with a pathogenic variant (PMID:27601257). - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 28, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 23, 2023 | - - |
not provided Uncertain:3Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Feb 25, 2014 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 19, 2023 | In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 27601257, 34426522, 22642865, 25356967) - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2023 | MCCC2: BS2 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Oct 09, 2015 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 10, 2022 | Variant summary: MCCC2 c.599T>A (p.Ile200Asn) results in a non-conservative amino acid change located in the Acetyl-coenzyme A carboxyltransferase, N-terminal domain (IPR011762) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0021 in 251438 control chromosomes, predominantly at a frequency of 0.0038 within the Non-Finnish European subpopulation in the gnomAD database, including 2 homozygotes. This frequency is approximately equal to the estimated maximal expected allele frequency for a pathogenic variant in MCCC2 causing Methylcrotonyl-CoA Carboxylase Deficiency (0.0038 vs 0.0042), suggesting that the variant may be a benign polymorphism found primarily in populations of Non-Finnish European origin. Nevertheless, c.599T>A has been reported in the literature in mothers who were identified with an elevated C5OH acylcarnitine level through their infant's newborn screening. These mothers were compound heterozygous with pathogenic variants but remained clinically asymptomatic (Grunert_2012, Shepard_2015, Fonseca_2016). These reports do not provide unequivocal conclusions about association of the variant with Methylcrotonyl-CoA Carboxylase Deficiency. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters (evaluation after 2014) cite the variant as likely benign and five ClinVar submitters (evaluation after 2014) cite it as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Methylcrotonyl-CoA carboxylase deficiency Benign:1
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 10, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at